During the pre-dialysis stage of chronic kidney disease, which treatment is associated with better survival in dialysis?;¿Qué intervenciones terapéuticas durante el estadio prediálisis de la enfermedad renal crónica se asocian a una mejor supervivencia en diálisis?

Nefrologia

Volumn 34, Issue 4, 2014, Pages 469-476

  Caravaca, Francisco ^a   Alvarado, Raúl ^a   García Pino, Guadalupe ^a   Martínez Gallardo, Rocío ^a   Luna, Enrique ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Angiotensin converting enzyme inhibitors; Dialysis; Mortality; Pre dialysis

Indexed keywords

DISEASE COURSE; FEMALE; HUMAN; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RENAL REPLACEMENT THERAPY; SURVIVAL; SURVIVAL RATE;

DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84905087034     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2014.Apr.12277     Document Type: Article

References (15)

1. Kopple JD. The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr 2005;81:1257-66.
2. Kramann R, Floege J, Ketteler M, Marx N, Brandenburg VM. Medical options to fight mortality in end-stage renal disease: a review of the literature. Nephrol Dial Transplant 2012;27:4298-307.
3. Fishbane S, Besarab A. Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol 2007;2:1274-82.
4. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24.
5. Ifudu O, Dawood M, Homel P, Friedman EA. Excess morbidity in patients starting uremia therapy without prior care by a nephrologist. Am J Kidney Dis 1996;28:841-5.
6. Bradbury BD, Fissell RB, Albert JM, Anthony MS, Critchlow CW, Pisoni RL, et al. Predictors of early mortality among incident US hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 2007;2:89-99.
7. Cravedi P, Remuzzi G, Ruggenenti P. Targeting the renin angiotensin system in dialysis patients. Semin Dial 2011;24:290-7.
8. Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ. Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int 2011;80:978-85.
9. Ahmed A, Fonarow GC, Zhang Y, Sanders PW, Allman RM, Arnett DK, et al. Renin-angiotensin inhibition in systolic heart failure and chronic kidney disease. Am J Med 2012;125:399-410.
10. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
11. Volpe M, Cosentino F, Tocci G, Palano F, Paneni F. Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep 2011;13:318-24.
12. Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD. Nephrol Dial Transplant 2009;24:1232-7.
13. Caravaca F, Arrobas M, Pizarro JL, Espárrago JF. Metabolic acidosis in advanced renal failure: differences between diabetic and nondiabetic patients. Am J Kidney Dis 1999;33:892-8.
14. Pisoni RL, Arrington CJ, Albert JM, Ethier J, Kimata N, Krishnan M, et al. Facility hemodialysis vascular access use and mortality in countries participating in DOPPS: an instrumental variable analysis. Am J Kidney Dis 2009;53:475-91.
15. Susantitaphong P, Altamimi S, Ashkar M, Balk EM, Stel VS, Wright S, et al. GFR at initiation of dialysis and mortality in CKD: a meta-analysis. Am J Kidney Dis 2012;59:829-40.